Search Results - "Foheidi, Meteb"

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis by Ibrahim, Ezzeldin M., Al-Foheidi, Meteb E., Al-Mansour, Mubarak M., Kazkaz, Ghieth A.

“…In a recent meta-analysis, we demonstrated that rich tumor-infiltrating lymphocytes (TILs) were significantly correlated to a favorable breast cancer (BC)…”
Get full text

Energy and caloric restriction, and fasting and cancer: a narrative review by Ibrahim, Ezzeldin M., Al-Foheidi, Meteb H., Al-Mansour, Mubarak M.

“…Dietary interventions have a significant impact on body metabolism. The sensitivity of cancer cells to nutrient and energy deficiency is an evolving…”
Get full text

Efficacy and safety of second‑generation CAR T‑cell therapy in diffuse large B‑cell lymphoma: A meta‑analysis by Mansour, Mubarak Al, Foheidi, Meteb Al, Ibrahim, Ezzeldin

“…Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3…”
Get full text

The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low‐ and middle‐income countries and the MENA region by Elghazaly, Hesham, Aref, Adel T., Anderson, Benjamin O., Arun, Banu, Yip, Cheng‐Har, Abdelaziz, Hany, Ghosn, Marwan, Al‐Foheidi, Meteb, Cardenosa, Gilda, Leung, Jessica W. T., Gado, Nivine, Balch, Charles M., Sabry, Mohamed, Ezz Elarab, Lobna, Giuliano, Armando E., El‐Zawahry, Heba M., Abdel Karim, Khaled, Nasr, Azza, Maki, Hussein, Chung, Hannah, Saadeddin, Ahmed, Abdelwahab, Manal M., Al Tahan, Fatina M., Chalabi, Nivine, Frolova, Mona, Kamal, Rasha M., Shehata, Mohamed A., Bahie Eldin, Nermean, Elghazawy, Hagar

“…In low‐middle income countries (LMICs) and the Middle East and North Africa (MENA) region, there is an unmet need to establish and improve breast cancer (BC)…”
Get full text

Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations by Elghazaly, Hesham, Azim, Hamdy A., Rugo, Hope S., Cameron, David, Swain, Sandra M., Curigliano, Giuseppe, Harbeck, Nadia, Tripathy, Debu, Arun, Banu, Aapro, Matti, Piccart, Martine, Cardoso, Fatima, Gligorov, Joseph, Elghazawy, Hagar, El Saghir, Nagi S., Penault‐Llorca, Frederique, Perez, Edith A., Poortmans, Philip, Abdelaziz, Hany, El‐Zawahry, Heba M., Kassem, Loay, Sabry, Mohamed, Viale, Giuseppe, Al‐Sukhun, Sana, Gado, Neven, Leung, Jessica W. T., Ezz Elarab, Lobna, Cardoso, Maria João, Abdel Karim, Khaled, Foheidi, Meteb, Elmaadawy, Merit M., Conte, Pierfranco, Selim, Ashraf S. M., Kandil, Alaa, Kamal, Rasha M., Paltuev, Ruslan M., Guarneri, Valentina, Abulkhair, Omalkhair, Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto, ElMahdy, Manal, Abdel‐Aziz, Ahmed M., Eldin, Nermean Bahie

“…Background The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic…”
Get full text

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis by Ibrahim, Ezzeldin M., Kazkaz, Ghieth A., Al-Mansour, Mubarak M., Al-Foheidi, Meteb E.

“…The association between PIK3CA mutation and resistance to anti-HER2 therapy (AHT) is not precisely defined. This meta-analysis intended to explore the clinical…”
Get full text

Is mammographic density a marker of breast cancer phenotypes? by Kanbayti, Ibrahem H., Rae, William I. D., McEntee, Mark F., Al-Foheidi, Meteb, Ashour, Sawsan, Turson, Smeera A., Ekpo, Ernest U.

“…Purpose To investigate the association between mammographic density (MD) phenotypes and both clinicopathologic features of breast cancer (BC) and tumor…”
Get full text

Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis by Ibrahim, Ezzeldin M, Abouelkhair, Khaled M, Kazkaz, Ghieth A, Elmasri, Osama A, Al-Foheidi, Meteb

“…Women treated for Hodgkin's lymphoma (HL) have an elevated risk of developing second breast cancer (SBC) compared with the general population. We planned this…”
Get full text

Correlation Between Oncotype Dx Recurrence Score and PREDICT Estimates in Early Breast Cancer: A Single Institution Experience by Ibrahim, Ezzeldin M, Al-Quzi, Bushra A, Shaheen, Ahmed Y, Kulak, Mohammed H, Refae, Ahmed A, Al-Foheidi, Meteb E

“…Oncotype Dx Recurrence Score (RS) is prognostic and predictive of chemotherapy benefit in women with node-negative and node-positive in hormone…”
Get full text

Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia by Al-Foheidi, Meteb H, Albeshri, Asem Mohammed, Moamenkahan, Safwan Noor, Abdullah, Abdulmajid Mohammed, Abualola, Muhannad Sadaqa, Alharbi, Muath Hamed, Refa, Ahmed A, Bayer, Ali M, Shaheen, Ahmed Y, Aga, Syed Sameer, Khan, Muhammad Anwar, Al-Mansour, Mubarak M, Ibrahim, Ezzeldin M

“…The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free…”
Get full text

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer by Elghazaly, Hesham, Rugo, Hope S, Azim, Hamdy A, Swain, Sandra M, Arun, Banu, Aapro, Matti, Perez, Edith A, Anderson, Benjamin O, Penault-Llorca, Frederique, Conte, Pierfranco, El Saghir, Nagi S, Yip, Cheng-Har, Ghosn, Marwan, Poortmans, Philip, Shehata, Mohamed A, Giuliano, Armando E, Leung, Jessica W T, Guarneri, Valentina, Gligorov, Joseph, Gulluoglu, Bahadir M, Abdel Aziz, Hany, Frolova, Mona, Sabry, Mohamed, Balch, Charles M, Orecchia, Roberto, El-Zawahry, Heba M, Al-Sukhun, Sana, Abdel Karim, Khaled, Kandil, Alaa, Paltuev, Ruslan M, Foheidi, Meteb, El-Shinawi, Mohamed, ElMahdy, Manal, Abulkhair, Omalkhair, Yang, Wentao, Aref, Adel T, Bakkach, Joaira, Bahie Eldin, Nermean, Elghazawy, Hagar

“…: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th…”
Get full text

Increased Risk of Second Lung Cancer in Hodgkin’s Lymphoma Survivors: A Meta-analysis by Ibrahim, Ezzeldin M., Kazkaz, Ghieth A., Abouelkhair, Khaled M., Al-Mansour, Mubarak M., Al-Fayea, Turki M., Al-Foheidi, Meteb, Bayer, Ali M., Elmasri, Osama A.

“…Background Patients treated for Hodgkin’s lymphoma (HL) have a higher risk of developing second lung cancer (SLC) compared with the general population. The aim…”
Get full text

Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma by Al-Jizani, Wafa'a A, Al-Mansour, Mubarak M, Al-Fayea, Turki M, Shafi, Ruaa U, Kazkaz, Ghieth A, Bayer, Ali M, Al-Foheidi, Meteb E, Ibrahim, Ezzeldin M

“…Bleomycin pulmonary toxicity (BPT) has been described in Hodgkin's lymphoma (HL) patients treated with bleomycin-containing chemotherapy regimens. We reviewed…”
Get full text

Granulocyte Colony Stimulating Factor (G-CSF) Induced Splenic Infarction in Breast Cancer Patient Treated with Dose-Dense Chemotherapy Regimen by Alshamrani, Majed A., Abdulrahim, Ahmed H., Al-Foheidi, Meteb

“…Introduction. Granulocyte colony-stimulating factor (G-CSF) is commonly used for prevention and treatment of febrile neutropenia among solid tumor patients. It…”
Get full text

Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial by AlSaleh, Khalid, Al Zahwahry, Heba, Bounedjar, Adda, Oukkal, Mohammed, Saadeddine, Ahmed, Mahfouf, Hassen, Bouzid, Kamel, Bensalem, Assia, Filali, Taha, Abdel-Razeq, Hikmat, Larbaoui, Blaha, Kandil, Alaa, Abulkhair, Omalkhair, Al Foheidi, Meteb, Errihani, Hassan, Ghosn, Marwan, Abdel-Aziz, Nashwa, Arafah, Maria, Boussen, Hamouda, Dabouz, Farida, Rasool, Haleem, Bahadoor, Mohun, Ayari, Jihen, Kullab, Sharif, Nabholtz, Jean-Marc

“…PURPOSE Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant…”
Get full text

Sleep quality and psychological disorders in breast cancer female patients receiving radiotherapy at a tertiary oncology center in West Saudi Arabia by Elamin, Nadia, Althebity, Nisreen, Alkhamisi, Taif A., Al-Foheidi, Meteb

“…Purpose Breast cancer is the most prevalent type of cancer among women worldwide. Many recently diagnosed and treated breast cancer patients complain about…”
Get full text

Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study by Yousef, Consuela Cheriece, Khan, Mansoor Ahmed, Almodaimegh, Hind, Alshamrani, Majed, Al-Foheidi, Meteb, AlAbdalkarim, Hana, AlJedai, Ahmed, Naeem, Anjum, Abraham, Ivo

“…This study estimated, for Saudi Arabia, the cost-efficiency of converting patients from reference Neupogen and Neulastim to one of two filgrastim biosimilars…”
Get more information

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant by Al-Saleh, Khalid A., El Zawahry, Heba Mohamed, Bounedjar, Adda, Oukkal, Mohammed, Saadeddin, Ahmed, Mahfouf, Hassen, Kamel, Bouzid, Bensalem, Assia, Abdel-Razeq, Hikmat, Kandil, Alaa, Abulkhair, Omalkhair A. M., Al-Foheidi, Meteb Owaish, Ghosn, Marwan, Boussen, Hamouda, Haddaoui, Abderrazak, Ayari, Jihene Braham, Alghamdi, Mohammed, Abdulaziz, Nashwa A., Kullab, Sharif Ahmed, Nabholtz, Jean-Marc A.

“…596 Background: Luminal, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) encompasses the most common subtype of breast…”
Get full text

Tailoring neo/adjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations by Elghazaly, Hesham, Azim, Hamdy, Rugo, Hope, Cameron, David, Swain, Sandra, Curigliano, Giuseppe, Harbeck, Nadia, Tripathy, Debu, Arun, Banu, Aapro, Matti, Piccart, Martine, Cardoso, Fatima, Gligorov, Joseph, Elghazawy, Hagar, El Saghir, Nagi, Penault-Llorca, Frederique, Perez, Edith, Poortmans, Philip, Abdelaziz, Hany, El-Zawahry, Heba, Kassem, Loay, Sabry, Mohamed, Viale, Giuseppe, Al-Sukhun, Sana, Gado, Neven, Leung, Jessica, Ezz Elarab, Lobna, Cardoso, Maria João, Abdel Karim, Khaled, Foheidi, Meteb, Elmaadawy, Merit, Conte, Pierfranco, Selim, Ashraf, Kandil, Alaa, Kamal, Rasha, Paltuev, Ruslan, Guarneri, Valentina, Abulkhair, Omalkhair, Zakaria, Omar, Golshan, Mehra, Orecchia, Roberto, Elmahdy, Manal, Abdel-Aziz, Ahmed, Eldin, Nermean Bahie

“…Abstract Background The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the…”
Get full text

Decisions on adjuvant chemotherapy for patients with breast cancer based on clinical and evolving Oncotype DX criteria by Zekri, Jamal, Al-Foheidi, Meteb Owaish, Alata, Maaz Kamal, Rasmy, Ayman Ahamd, Rasool, Haleem J., Abdelrahman, Hossam A., Hussain, Adnan, Sorour, Yasser, Mashhour, Miral

“…Abstract only e12009 Background: Oncotype-DX assay recurrence score (ODX-RS) cut-off values have recently changed in response to the results of the TAILOR-X…”
Get full text